Evaluation of psoriasis patients with long-term topical corticosteroids for their risk of developing adrenal insufficiency, Cushing's syndrome and osteoporosis

AbstractPurpose In this study, we will investigate the possible side effects of psoriasis patients using long-term topical corticosteroids (TCS) such as adrenal insufficiency, Cushing's Syndrome (CS) and osteoporosis and determine how these side effects develop.Material and Methods Forty-nine p...

Full description

Saved in:
Bibliographic Details
Main Authors: Betul Erdem (Author), Muzeyyen Gonul (Author), Ilknur Ozturk Unsal (Author), Seyda Ozdemir Sahingoz (Author)
Format: Book
Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3eac9e9dd89e47ac8f128cfca6f00b4a
042 |a dc 
100 1 0 |a Betul Erdem  |e author 
700 1 0 |a Muzeyyen Gonul  |e author 
700 1 0 |a Ilknur Ozturk Unsal  |e author 
700 1 0 |a Seyda Ozdemir Sahingoz  |e author 
245 0 0 |a Evaluation of psoriasis patients with long-term topical corticosteroids for their risk of developing adrenal insufficiency, Cushing's syndrome and osteoporosis 
260 |b Taylor & Francis Group,   |c 2024-12-01T00:00:00Z. 
500 |a 10.1080/09546634.2023.2298880 
500 |a 1471-1753 
500 |a 0954-6634 
520 |a AbstractPurpose In this study, we will investigate the possible side effects of psoriasis patients using long-term topical corticosteroids (TCS) such as adrenal insufficiency, Cushing's Syndrome (CS) and osteoporosis and determine how these side effects develop.Material and Methods Forty-nine patients were included in the study. The patients were divided into two groups based on the potency of the topical steroid they took and the patients' ACTH, cortisol and bone densitometer values were evaluated.Results There was no significant difference between the two groups regarding the development of surrenal insufficiency, CS and osteoporosis. One patient in group 1 and 4 patients in group 2 were evaluated as iatrogenic CS. ACTH stimulation tests of these patients in group 2 showed consistent results with adrenal insufficiency, while no adrenal insufficiency was detected in the patient in Group 1. Patients who used more than 50g of superpotent topical steroids per week compared to patients who used 50g of superpotent topical steroids per week. It was identified that patients who used more than 50g of superpotent topical steroids had significantly lower cortisol levels, with a negatively significant correlation between cortisol level and the amount of topical steroid use (p < .01).Osteoporosis was detected in 3 patients in group 1 and 8 patients in Group 2. Because of the low number of patients between two groups, statistical analysis could not be performed to determine the risk factors.Conclusions Our study is the first study that we know of that investigated these three side effects. We have shown that the development of CS, adrenal insufficiency and osteoporosis in patients who use topical steroids for a long time depends on the weekly TCS dosage and the risk increases when it exceeds the threshold of 50 grams per week. therefore, our recommendation would be to avoid long-term use of superpotent steroids and to choose from the medium-potent group if it is to be used. 
546 |a EN 
690 |a Iatrogenic cushing's syndrome 
690 |a osteoporosis 
690 |a psoriasis 
690 |a adrenal insufficiency 
690 |a topical corticosteroid 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Journal of Dermatological Treatment, Vol 35, Iss 1 (2024) 
787 0 |n https://www.tandfonline.com/doi/10.1080/09546634.2023.2298880 
787 0 |n https://doaj.org/toc/0954-6634 
787 0 |n https://doaj.org/toc/1471-1753 
856 4 1 |u https://doaj.org/article/3eac9e9dd89e47ac8f128cfca6f00b4a  |z Connect to this object online.